136823-41-1

Usage

Uses

Used in Flavor and Fragrance Industry:
Methyl (2E)-3-Cyclopentylprop-2-Enoate is used as a flavoring agent for its pleasant, fruity odor, enhancing the sensory experience of various food products and beverages.
Used in Pharmaceutical Industry:
Methyl (2E)-3-Cyclopentylprop-2-Enoate is used as a synthetic building block in the production of pharmaceuticals, contributing to the development of new drugs and medicinal compounds.
Used in Organic Compounds Synthesis:
Methyl (2E)-3-Cyclopentylprop-2-Enoate is utilized as a key intermediate in the synthesis of various organic compounds, facilitating the creation of a wide range of chemical products.

Upstream product

• 872-53-7 cyclopentanealdehyde 
• 5927-18-4 trimethyl phosphonoacetate 
• 137-43-9 Cyclopentyl bromide 
• 67-56-1 methanol 
• 5732-89-8 3-cyclopentyl acrylic acid 
• 287-92-3 Cyclopentane 
• 922-67-8 propynoic acid methyl ester 
• 930-51-8 cyclopentylacetylene 
• 124-38-9 carbon dioxide 
• 74-88-4 methyl iodide 

Downstream Products

• 941678-49-5 ruxolitinib 
• 1146629-83-5 (R)-3-(4-bromo-1H-pyrazol-1-yl)-3-cyclopentylpropanecarbonitrile 
• 941685-37-6 (3S)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile 
• 1146629-84-6 (3R)-3-cyclopentyl-3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl]propanenitrile 
• 1319734-50-3 C₁₅H₂₁NO₃ 
• 1319734-25-2 C₂₅H₃₇N₃O₃ 

Relevant academic research and scientific papers

Intermediate of JAK inhibitor, and preparation method thereof

The present invention relates to a novel key intermediate of a JAK inhibitor ruxolitinib, and a preparation method thereof, wherein the chemical name of the intermediate is (R)-3-(4-boric acid-1H-pyrazole-1-yl)-3-cyclopentylpropionitrile. According to the present invention, the new ruxolitinib preparation route is provided, wherein each reaction of the route has the high yield, the total yield ofthe route is high, the purity of the obtained product is good, the post-treatment of the reaction is simple, and column chromatography is not required; by adopting the route, the required raw materials or catalysts and other materials are relatively easy to obtain; and compared to the method in the prior art, the method of the present invention is economical and is suitable for industrial production.

Preparation methods of JAK inhibitor and salt thereof

The present invention relates to preparation methods of a JAK inhibitor and a salt thereof. The preparation method comprises: (1) carrying out a Suzuki coupling reaction on (R)-3-(4-boronic acid-1H-pyrazol-1-yl)-3-cyclopentylpropionitrile and 6-halogen-5-(2-methoxyvinyl)pyrimidin-4-ylamine to generate (3R)-cyclopentyl-3-[4-(5-(2-methoxyvinyl)pyrimidin-4-ylamine)pyrazol-1-yl]propionitrile; and (2)carrying out a protection group removing and ring-closure reaction on the (3R)-cyclopentyl-3-[4-(5-(2-methoxyvinyl)pyrimidin-4-ylamine)pyrazol-1-yl]propionitrile to generate a JAK inhibitor ruxolitinib. According to the present invention, the new ruxolitinib preparation route is provided, wherein each reaction of the route has the high yield, the total yield of the route is high, the purity of theobtained product is good, the post-treatment of the reaction is simple, and column chromatography is not required; by adopting the route, the required raw materials or catalysts and other materials are relatively easy to obtain; and compared to the method in the prior art, the method of the present invention is economical and is suitable for industrial production.

Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5- dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: A highly potent orally available CCR5 selective antagonist

Based on the original spirodiketopiperazine design framework, further optimization of an orally available CCR5 antagonist was undertaken. Structural hybridization of the hydroxylated analog 4 derived from one of the oxidative metabolites and the new orally available non-hydroxylated benzoic acid analog 5 resulted in another potent orally available CCR5 antagonist 6a as a clinical candidate. Full details of a structure-activity relationship (SAR) study and ADME properties are presented.

Functionalisation of cycloalkanes: The photomediated reaction of cycloalkanes with alkynes

Using a standard mercury vapour lamp or sunlight, and in the presence of a soluble or polymer-bound photomediator such as benzophenone, cycloalkanes can be functionalised by insertion of alkynes containing electron-withdrawing groups into a C-H bond.

From Stoichiometry to Catalysis: Electroreductive Coupling of Alkynes and Carbon Dioxide with Nickel-Bipyridine Complexes. Magnesium Ions as the Key for Catalysis

The incorporation of carbon dioxide into nonactivated alkynes catalyzed by electrogenerated nickel-bipyridine complexes affords α,β-unsaturated acids in moderate to good yields.The electrocarboxylation reaction was undertaken on a preparative scale in the presence of a sacrificial magnesium anode: the formation of acids from alkynes is stoichiometric with respect to the nickel complex if performed in a two-compartment cell but can be made catalytic in a single-compartment cell.An intermediate nickelacycle was isolated from the reaction with 4-octyne.The cleavage ofthis metallacycle by magnesium ions is the key step to explain catalysis.